Latest Period
Q1 2026
Security Snapshot
Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO) Institutional Ownership
CUSIP: 98937L105
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
137
Shares (Excl. Options)
54,499,375
Price
$19.55
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- ZBIO on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 54,499,375
- Total 13F value
- $1,065,366,720
- Portfolio coverage rank
- 0%
- Share change
- +12,530,847
- Value change
- +$196,744,530
- Number of holders
- 137
- Shares outstanding
- 63,278,585
- SEC-reported price per share
- $19.84
- Insider filing price
- $19.84
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ZBIO - Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 98937L105.
- 137 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 118 to 137 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,504,857,337 to $1,065,366,720.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 137 institutions filings for Q1 2026.
Security key
98937L105
Latest holder period
Q1 2026
13F holders
137
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
ZBIO full holder history
Zenas BioPharma, Inc. SEC filings
Zenas BioPharma, Inc. company facts
Zenas BioPharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98937L105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
ZBIO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 14% | +30% | $277,876,336 | +$109,228,632 | 7,652,255 | +65% | FMR LLC | 31 Dec 2025 |
| SR ONE CAPITAL MANAGEMENT, LLC | 9.4% | $111,851,442 | 5,037,854 | SR One Capital Management, LLC | 09 Oct 2025 | |||
| InnoCare Pharma Inc. | 9.4% | $111,026,500 | 5,000,000 | InnoCare Pharma Inc. | 07 Oct 2025 | |||
| Enavate Sciences GP, LLC | 7.3% | $87,013,952 | 3,919,159 | Enavate Sciences GP, LLC | 09 Oct 2025 | |||
| MOULDER LEON O JR | 5.1% | +6% | $67,767,315 | +$4,017,777 | 3,220,880 | +6.3% | MOULDER LEON O JR | 29 Apr 2026 |
| Longitude Capital Partners IV, LLC | 4.9% | $58,425,578 | 2,631,522 | Patrick G. Enright | 09 Oct 2025 | |||
| Novo Holdings A/S | 4.7% | -12% | $44,400,000 | -$4,772,267 | 2,000,000 | -9.7% | Novo Holdings A/S | 30 Sep 2025 |
As of 31 Mar 2026, 137 institutional investors reported holding 54,499,375 shares of Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO). This represents 86% of the company’s total 63,278,585 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
76%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 9,082,000 | +18% | 0.01% | $177,553,101 |
| SR One Capital Management, LP | 8% | 5,037,854 | 0% | 11% | $98,490,046 |
| NEA Management Company, LLC | 6.4% | 4,023,219 | +14% | 4.5% | $78,653,931 |
| ENAVATE SCIENCES GP, LLC | 6.2% | 3,919,159 | 0% | 22% | $76,619,558 |
| FEDERATED HERMES, INC. | 4.9% | 3,127,031 | +15% | 0.1% | $61,133,456 |
| Polar Capital Holdings Plc | 4% | 2,548,444 | +141% | 0.22% | $49,822,080 |
| Capital International Investors | 3.8% | 2,434,000 | 0.01% | $47,584,700 | |
| Fairmount Funds Management LLC | 3.7% | 2,359,025 | +6.8% | 3.3% | $46,118,939 |
| BlackRock, Inc. | 3.2% | 2,037,548 | +15% | 0% | $39,834,063 |
| NVP ASSOCIATES, LLC | 2.9% | 1,838,482 | 0% | 20% | $35,942,323 |
| STATE STREET CORP | 2.3% | 1,470,923 | +236% | 0% | $28,756,545 |
| WELLINGTON MANAGEMENT GROUP LLP | 2% | 1,246,053 | +46% | 0% | $24,360,335 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2% | 1,245,391 | 0% | 0% | $24,347,394 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.8% | 1,135,935 | 2.6% | $22,207,529 | |
| EcoR1 Capital, LLC | 1.2% | 789,500 | 0% | 0.66% | $15,434,725 |
| Balyasny Asset Management L.P. | 1.1% | 667,070 | +245% | 0.03% | $13,041,219 |
| ArrowMark Colorado Holdings LLC | 1% | 658,909 | -12% | 0.34% | $12,881,671 |
| GEODE CAPITAL MANAGEMENT, LLC | 1% | 655,785 | +11% | 0% | $12,823,976 |
| Pivotal bioVenture Partners Investment Advisor LLC | 0.94% | 591,991 | 0% | 4.1% | $11,573,424 |
| Woodline Partners LP | 0.93% | 590,525 | 0.04% | $11,544,764 | |
| GREAT POINT PARTNERS LLC | 0.83% | 524,066 | 2.5% | $10,245,490 | |
| Rock Springs Capital Management LP | 0.79% | 502,077 | 0% | 0.58% | $9,815,605 |
| MARSHALL WACE, LLP | 0.79% | 501,928 | +6969% | 0.01% | $9,812,692 |
| MILLENNIUM MANAGEMENT LLC | 0.75% | 476,818 | +870% | 0.01% | $9,321,792 |
| NEXTBio Capital Management LP | 0.67% | 426,736 | +33% | 3.9% | $8,342,689 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Latest
Q1 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 54,499,375 | $1,065,366,720 | +$196,744,530 | $19.55 | 137 |
| 2025 Q4 | 41,561,367 | $1,504,857,337 | +$255,199,550 | $36.31 | 118 |
| 2025 Q3 | 34,774,383 | $771,813,059 | +$23,276,708 | $22.20 | 78 |
| 2025 Q2 | 34,055,191 | $329,977,952 | +$15,611,752 | $9.69 | 72 |
| 2025 Q1 | 32,489,801 | $256,715,238 | +$5,759,402 | $7.90 | 67 |
| 2024 Q4 | 31,699,756 | $259,632,936 | +$20,083,837 | $8.19 | 65 |
| 2024 Q3 | 24,771,152 | $418,526,187 | +$418,475,122 | $16.92 | 44 |